Woojin B&G Receives Growing Interest for Iridovirus Vaccine... Accelerates Export Expansion

Woojin B&G, a company specializing in veterinary pharmaceuticals, is accelerating its efforts to enter the Asian market with its independently developed iridovirus vaccine.

On May 20, Woojin B&G announced that it had presented the field efficacy of its iridovirus vaccine, 'Immunis MegaVac®', at the 2025 International Symposium of the Korean Society of Fisheries and Sciences.

This served as an official opportunity to showcase the vaccine's excellent safety and efficacy to both domestic and international academic communities. Iridovirus is a virus that primarily affects species such as red sea bream and striped beakfish, as well as sea bass, during the high-temperature summer season when water temperatures exceed 25°C. Until now, there has been no effective treatment, resulting in significant losses for fish farmers.

In response, Woojin B&G began developing an iridovirus vaccine. The company obtained final product approval in 2021 and, in 2022, launched Immunis MegaVac, the first fish vaccine of its kind in Korea.

Immunis MegaVac has demonstrated effective infection prevention, showing a high survival rate of over 80% in striped beakfish farms.

Currently, the vaccine is mainly supplied in the Tongyeong and Geoje regions of Gyeongnam, and the supply network is now expanding to areas such as Yeosu in Jeonnam.

Since its launch, the product has recorded rapid market expansion, posting a compound annual growth rate (CAGR) of over 120%.

With this academic conference presentation as a turning point, Woojin B&G plans to accelerate its efforts to pioneer the global market for K-vaccines and expand exports, with the iridovirus vaccine at the forefront.

The vaccine is already attracting significant interest from major partners in key Asian aquaculture countries, including Japan, Indonesia, Taiwan, Vietnam, and Thailand, with active discussions underway regarding exports.

A Woojin B&G representative stated, "Starting with Immunis MegaVac, we aim to become a leading vaccine specialist representing Korea in the global aquaculture bio sector, leveraging our accumulated biotechnology and field-oriented research and development."